Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses YMAB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named YMAB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Rossi | $705,600 | $0 | $1,170,732 | $2,288,662 | $392,596 | $0 | $0 | $4,557,590 |
| President and Chief Executive Officer | ||||||||
| Peter Pfreundschuh | 252,083 | 0 | 573,620 | 1,580,609 | 98,405 | 0 | 0 | 2,504,717 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Thomas Gad | 579,752 | 0 | 213,928 | 949,349 | 248,134 | 0 | 84,000 | 2,075,163 |
| Founder, Chief Business Officer and Vice Chairman of the Board of Directors | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Michael Rossi | $4,557,590 | $3,110,553 | — | +1,447,037 |
| Peter Pfreundschuh | 2,504,717 | — | — | — |
| Thomas Gad | 2,075,163 | 2,454,483 | — | −379,320 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Rossi | PSU | 54,000 | — | $422,820 |
| Peter Pfreundschuh | RSU | 46,000 | — | 360,180 |
| Michael Rossi | RSU | 35,700 | — | 279,531 |
| Thomas Gad | RSU | 22,100 | — | 173,043 |
| Michael Rossi | Option | 448,634 | 5.75 | — |
| Thomas Gad | RSU | 27,001 | — | 211,418 |
| Michael Rossi | Option | 214,200 | 14.36 | — |
| Thomas Gad | Option | 27,588 | 15.73 | — |
| Thomas Gad | Option | 21,288 | 9.52 | — |
| Thomas Gad | Option | 126,235 | 4.7 | — |
| Thomas Gad | Option | 54,690 | 5.75 | — |
| Thomas Gad | Option | 132,500 | 9.83 | — |
The Compensation Committee generally targets the 50th percentile of the peer group for base salary and target total cash and between the 50th and 75th percentile for long-term equity incentives for our executive officers.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon's Human Capital Solutions practice (division of Aon plc) |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-07-11 | 27,011,027 | 3,838,565 | 1,755 | 87.56% | Passed |
| 2024 | 2024-06-11 | 27,772,834 | 721,693 | 521 | 97.47% | Passed |
| 2023 | 2023-06-08 | 15,934,564 | 5,999,462 | 8,132 | 72.65% | Passed |
| 2022 | 2022-06-09 | 15,782,697 | 11,179,894 | 534,109 | 58.54% | Passed |
| 2021 | 2021-06-10 | 20,503,309 | 10,933,563 | 1,225 | 65.22% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-07-11 | 87.56%a |
| 2024 | 2024-06-11 | 97.47%b |
| 2023 | 2023-06-08 | 72.65%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mary TagliaferriIndependent · Compensation · Not standing for re-election | $31,301 | $116,954 | $454,242 | — | $0 | $602,497 |
| James I. HealyIndependent · Board Chair · Audit | 95,000 | 41,975 | 125,817 | — | 0 | 262,792 |
| David N. GillIndependent · Audit (Chair) · Compensation · Nominating/Governance | 82,500 | 41,975 | 125,817 | — | 0 | 250,292 |
| Laura J. HamillIndependent · Compensation (Chair) · Nominating/Governance | 70,000 | 41,975 | 125,817 | — | 0 | 237,792 |
| Ashutosh TyagiIndependent · Nominating/Governance (Chair) | 60,000 | 41,975 | 125,817 | — | 0 | 227,792 |
| Johan Wedell-WedellsborgIndependent · Audit | 60,000 | 41,975 | 125,817 | — | 0 | 227,792 |
| Dr. Gérard BerIndependent · Compensation · Departed during FY | 40,061 | 0 | 0 | — | 0 | 40,061 |
| Thomas GadEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Michael RossiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $170,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $438,862 |
| Equity awards (grant-date value) | $326,829 |
| All other compensation | $0 |
| Total cost of the board | $765,691 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Y-mAbs Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Y-mAbs Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | $807,692 | $8,274,785 | $7,688,560 | $759,488 | $17,544,525 |
| 2 | SpringWorks Therapeutics, Inc. | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 3 | BioCryst Pharmaceuticals, Inc. | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 4 | Arcus Biosciences, Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 5 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 6 | Deciphera Pharmaceuticals, Inc. | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 7 | Agios Pharmaceuticals, Inc. | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 8 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 9 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 10 | UroGen Pharma Ltd. | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 11 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 12 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 13 | bluebird bio, Inc. | 2023 | Andrew Obenshain | 681,657 | 863,590 | 1,142,440 | 348,024 | 3,049,181 |
| 14 | Karyopharm Therapeutics Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 15 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 16 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
| 17 | Atara Biotherapeutics, Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
| — | G1 Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Y-mAbs Therapeutics | 85.6% | PSU 34 · Options 33 · RSU 33 | No | Aon's Human Capital Solutions practice (division of Aon plc) |
| Agios Pharmaceuticals, Inc. | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| Arcus Biosciences, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Atara Biotherapeutics, Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| BioCryst Pharmaceuticals, Inc. | 170% | not disclosed | not disclosed | Aon Human Capital Solutions (division of Aon plc) |
| bluebird bio, Inc. | 85% | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Aon plc (Human Capital Solutions practice) |
| Deciphera Pharmaceuticals, Inc. | 110% | Options 50 · PSU 50 | No | Pearl Meyer & Partners, LLC |
| G1 Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Heron Therapeutics, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Compensia, Inc. |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Karyopharm Therapeutics Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025) |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance LLC |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| SpringWorks Therapeutics, Inc. | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon plc (Human Capital Solutions practice) |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| UroGen Pharma Ltd. | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Rossi | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Summary Compensation Table” · page 39. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604 |
| 2 | Section 01, Peter Pfreundschuh | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Summary Compensation Table” · page 39. As printed: 2,504,717. Filing ↗machine: t100 · r11 · c23 · span 639226–639235 |
| 3 | Section 01, Thomas Gad | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Summary Compensation Table” · page 39. As printed: 2,075,163. Filing ↗machine: t100 · r8 · c23 · span 618762–618771 |
| 4 | Section 08, Mary Tagliaferri | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 602,497. Filing ↗machine: t131 · r8 · c12 · span 1135124–1135131 |
| 5 | Section 08, James I. Healy | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 262,792. Filing ↗machine: t131 · r5 · c12 · span 1124894–1124901 |
| 6 | Section 08, David N. Gill | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 250,292. Filing ↗machine: t131 · r4 · c12 · span 1121371–1121378 |
| 7 | Section 08, Laura J. Hamill | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 237,792. Filing ↗machine: t131 · r6 · c12 · span 1128162–1128169 |
| 8 | Section 08, Ashutosh Tyagi | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 227,792. Filing ↗machine: t131 · r7 · c12 · span 1131685–1131692 |
| 9 | Section 08, Johan Wedell-Wedellsborg | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 227,792. Filing ↗machine: r9 · c12 · span 1138654–1138661 |
| 10 | Section 08, Dr. Gérard Ber | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 40,061. Filing ↗machine: t131 · r3 · c3 · span 1115621–1115627 |
| 11 | Section 08, Thomas Gad | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Michael Rossi | DEF 14A | 2025-05-30 | 0001558370-25-008299 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 06, 2025 vote | Form 8-K | 2025-07-15 | 0001104659-25-068099 | Item 5.07 · say-on-pay result. As reported: 87.56% (votes for as printed: 27,011,027). Filing ↗ |
| 14 | Section 06, 2024 vote | Form 8-K | 2024-06-13 | 0001104659-24-071250 | Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 27,772,834). Filing ↗ |
| 15 | Section 06, 2023 vote | Form 8-K | 2023-06-09 | 0001104659-23-070029 | Item 5.07 · say-on-pay result. As reported: 72.65% (votes for as printed: 15,934,564). Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | computed | Cash 438,862 + equity 326,829 + all other 0 = 765,691, summed across the director compensation table rows.machine: formula: Σ = 765,691 |
| 18 | Rhythm Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 19 | SpringWorks Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194 |
| 20 | BioCryst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 21 | Arcus Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 22 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 23 | Deciphera Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2024-04-25 | 0001654151-24-000012 | CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 24 | Agios Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 25 | Rigel Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001034842-26-000023 | CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068 |
| 26 | Y-mAbs Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604 |
| 27 | UroGen Pharma Ltd., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014237 | CEO total compensation as printed in UroGen Pharma Ltd.'s own proxy. As printed: 4,310,624. Filing ↗machine: r1 · c29 · span 562926–562935 |
| 28 | Heron Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-196306 | CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 29 | Puma Biotechnology, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001437749-26-013671 | CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. Filing ↗machine: t56 · r1 · c29 · span 540970–540979 |
| 30 | bluebird bio, Inc., Section 10b CEO total | DEF 14A | 2024-09-26 | 0001293971-24-000049 | CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796 |
| 31 | Karyopharm Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001503802-26-000023 | CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348 |
| 32 | MacroGenics, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001125345-26-000021 | CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198 |
| 33 | Iovance Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050458 | CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. Filing ↗machine: t133 · r6 · c16 · span 797910–797919 |
| 34 | Atara Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177285 | CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. Filing ↗machine: span 714260–714269 |
| 35 | Section 10a, Deciphera Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001654151-24-000012 | Deciphera Pharmaceuticals, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 36 | Section 10a, Heron Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-196306 | Heron Therapeutics, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 37 | Section 10a, MacroGenics, Inc. reciprocity | DEF 14A | — | 0001125345-26-000021 | MacroGenics, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 38 | Section 10a, SpringWorks Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 39 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 40 | Section 10a, UroGen Pharma Ltd. reciprocity | DEF 14A | — | 0001437749-26-014237 | UroGen Pharma Ltd. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 41 | Section 10a, Puma Biotechnology, Inc. reciprocity | DEF 14A | — | 0001437749-26-013671 | Puma Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 42 | Section 10a, Rigel Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001034842-26-000023 | Rigel Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 43 | Section 10a, Rhythm Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 44 | Section 10a, Agios Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 45 | Section 10a, BioCryst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |
| 46 | Section 10a, Iovance Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050458 | Iovance Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗ |